deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT00601003

Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma

A Phase II Trial of Nifurtimox for Refractory or Relapsed Neuroblastoma or Medulloblastoma.

Sponsor: Bayer

Conditions Medulloblastoma Neuroblastoma
Interventions Cyclophosphamide Nifurtimox Topotecan
Updated 19 times since 2017 Last updated: Aug 2, 2024 Started: Jan 14, 2008 Primary completion: Apr 28, 2020 Completion: Oct 28, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Medulloblastoma and Neuroblastoma, this trial is completed. The trial is conducted by Bayer and has accumulated 19 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~May 2017 · 3 months · monthly snapshot~May 2017 – ~Jun 2018 · 13 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Aug 2019 · 12 months · monthly snapshot~Aug 2019 – ~Oct 2019 · 2 months · monthly snapshot~Oct 2019 – ~Dec 2020 · 14 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Mar 2022 · 6 months · monthly snapshot~Mar 2022 – ~May 2022 · 2 months · monthly snapshot~May 2022 – ~Oct 2022 · 5 months · monthly snapshot~Oct 2022 – ~Feb 2023 · 4 months · monthly snapshot~Feb 2023 – ~Oct 2023 · 8 months · monthly snapshot~Oct 2023 – ~May 2024 · 7 months · monthly snapshot~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

19 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. May 2024 — Jul 2024 [monthly]

    Completed PHASE2

  5. Oct 2023 — May 2024 [monthly]

    Completed PHASE2

▶ Show 14 earlier versions

  1. Feb 2023 — Oct 2023 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  2. Oct 2022 — Feb 2023 [monthly]

    Active Not Recruiting PHASE2

  3. May 2022 — Oct 2022 [monthly]

    Active Not Recruiting PHASE2

  4. Mar 2022 — May 2022 [monthly]

    Active Not Recruiting PHASE2

  5. Sep 2021 — Mar 2022 [monthly]

    Active Not Recruiting PHASE2

  6. Jan 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE2

  7. Dec 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  8. Oct 2019 — Dec 2020 [monthly]

    Active Not Recruiting PHASE2

  9. Aug 2019 — Oct 2019 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  10. Aug 2018 — Aug 2019 [monthly]

    Recruiting PHASE2

  11. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE2

  12. May 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

  13. Feb 2017 — May 2017 [monthly]

    Recruiting PHASE2

  14. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Jan 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bayer
  • Giselle Sholler
Data source: Milton S. Hershey Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Boston, United States , Charleston, United States , Charlotte, United States , Dallas, United States , Grand Rapids, United States , Hartford, United States , Hershey, United States , Honolulu, United States , Houston, United States , Kansas City, United States and 5 more locations